We’re working for a world where no one dies from skin cancer by deploying our AI medical device, DERM, to create the world’s most advanced skin cancer pathways. Skin Analytics are proud to work with NHS dermatology teams to deploy AI powered skin cancer pathways. Our pathways enable NHS organisations to discharge benign lesions earlier in the pathway and therefore tackle backlog, free up out-patient delays and crucially, reserve limited dermatology capacity to prioritise patients with skin cancer by focusing on providing potentially life-saving treatment. Some things we’re a little bit proud of: 🚀We’ve worked with the NHS since 2020 and DERM is currently deployed across 25 primary and secondary care organisations 🥇We’re the first and only AI skin cancer pathway within the NHS ✅ DERM is recommended by the National Institute for Health and Care Excellence (NICE) ✅DERM is the only Class III CE marked AI as a Medical Device for skin cancer 🤯DERM is used in pathways that have seen over 170,000 NHS patients and identified more than 15,500 cancers 💪We’ve helped NHS organisations avoid up to 95% of face-to-face appointments in secondary care 🤳We provide Bupa and Vitality's remote skin assessment service ❤️Everything we do is in pursuit of better patients outcomes that are sustainable for health systems, globally
Skin Analytics is a leading health tech company specializing in AI-powered skin cancer pathways for dermatology teams. They are seeking a Product Marketing Manager to drive growth by translating customer insights into commercial strategies, managing senior stakeholders, and executing go-to-market programs for the NHS, especially in the EU and the US. This role requires frequent travel and collaboration with multiple departments.
We’re working for a world where no one dies from skin cancer by deploying our AI medical device, DERM, to create the world’s most advanced skin cancer pathways. Skin Analytics are proud to work with NHS dermatology teams to deploy AI powered skin cancer pathways. Our pathways enable NHS organisations to discharge benign lesions earlier in the pathway and therefore tackle backlog, free up out-patient delays and crucially, reserve limited dermatology capacity to prioritise patients with skin cancer by focusing on providing potentially life-saving treatment. Some things we’re a little bit proud of: 🚀We’ve worked with the NHS since 2020 and DERM is currently deployed across 25 primary and secondary care organisations 🥇We’re the first and only AI skin cancer pathway within the NHS ✅ DERM is recommended by the National Institute for Health and Care Excellence (NICE) ✅DERM is the only Class III CE marked AI as a Medical Device for skin cancer 🤯DERM is used in pathways that have seen over 170,000 NHS patients and identified more than 15,500 cancers 💪We’ve helped NHS organisations avoid up to 95% of face-to-face appointments in secondary care 🤳We provide Bupa and Vitality's remote skin assessment service ❤️Everything we do is in pursuit of better patients outcomes that are sustainable for health systems, globally